Lipopolysaccharide (LPS) is a commonly used agent for induction of neuroinflammation in preclinical studies. Upon injection, LPS causes activation of microglia and astrocytes, whose metabolism alters to favor glycolysis. Assessing in vivo neuroinflammation and its modulation following therapy remains challenging, and new noninvasive methods allowing for longitudinal monitoring would be highly valuable.
| INTRODUCTION
Lipopolysaccharide (LPS) is a bacterial endotoxin commonly used to induce neuroinflammation and generate preclinical animal models of the inflammatory response alone, 1 or to help model complex neurological disorders such as Alzheimer's disease (AD). 2 Upon in vivo injection (intravenous, 3 intraperitoneal 4 or intracranial 5 ), LPS causes an inflammatory response, with release of proinflammatory cytokines such as tumor necrosis factor alpha, following immune cell recognition of LPS by their cell surface receptors (specifically toll-like receptor 4 [TLR4]). 6 Activation of microglia similarly occurs via TLR-4 recognition in AD, in that case due to the presence of the aberrant protein amyloid-β. 7 Studies have shown that intracranial injection of LPS into the mouse brain leads to an increased number and activation of microglia 2, 8 as well as increased astrogliosis. 9,10 These cellular traits have been observed in the brains of patients with neurodegenerative diseases such as Parkinson's disease and AD. 11 In Parkinson's disease, for example, increased cytokine levels and activation of microglia and astrocytes (as induced in models using LPS) have been associated with the disease's characteristic loss of dopaminergic neurons. [12] [13] [14] Following LPS-induced activation, both activated microglia and astrocytes demonstrate metabolic reprogramming, in particular a shift towards increased glycolysis. This has been shown in BV-2 mouse microglia by Voloboueva et al., 15 where LPS induced an increase in lactate production and a decrease in mitochondrial oxygen consumption and ATP production, assessed by both biochemical assays and a Seahorse extracellular flux analyzer. Further, Klimaszewska-Łata et al. 16 showed pyruvate dehydrogenase inhibition in the N9 mouse microglial cell line following LPS treatment. Primary astrocytes in culture were similarly activated (by a combinatory LPS/interferon-gamma treatment) by Bal-Price et al. 17 and were shown to produce more lactic acid, as measured by levels in the growth medium.
With the knowledge that neuroinflammation is associated with changes in the metabolism of immune and glial cells, one could use noninvasive, clinically translatable metabolic imaging approaches to enable the longitudinal monitoring of neuroinflammatory status, as well as response to anti-inflammatory therapies. Magnetic resonance (MR) techniques include 1 H MR spectroscopy (MRS), and studies using this method have suggested that certain 1 H-visible metabolites, such as myoinositol, choline and total creatine, could be linked to inflammation, for example in multiple sclerosis (MS) patients. 18 Increased lactate, as detected by 1 H MRS, has also been reported in patients with traumatic brain injury (TBI), 19 and preclinical work by Lodygensky et al. 20 showed increased lactate in LPS-injected rat pups. However, to date 1 H MRS is only used in a narrow set of clinical pathologies, at those centers with the appropriate expertise to interpret the data. Although optimization of 1 H MRS for the assessment of neuroinflammation is ongoing, 21 this methodology is not yet standard clinical procedure, and alternative strategies are needed. 13 C MRS holds great promise for assessing in vivo metabolism. It allows identification of steady-state metabolism in the brain after intravenous administration of 13 C-labeled substrates over more than 1 hour, 22 and has been applied in the healthy mouse, 23 rat 24 and human brain, 25 the healthy aging brain 26 and AD. 27 However, these methods require long infusions of substrate and extended scan times, which limits clinical translation. Hyperpolarized (HP) 13 C MRS 28 is a rapidly expanding alternative imaging technology for visualizing in vivo metabolism. 29, 30 Acquisition occurs in a matter of minutes, thanks to the 10 000-fold increase in sensitivity over thermal 13 C MRS. Thus far, HP 13 C MRS has been particularly informative on the conversion of HP [1-13 C] pyruvate to [1-13 C] lactate via the enzyme lactate dehydrogenase, and there has been a focus on applications in cancer 31, 32 and cardiovascular disease. 33 Applications of HP 13 C MRS continue to expand, with a wide range of studies including investigations into bacteria, 34 healthy and diseased liver, [35] [36] [37] kidneys, 38 skeletal muscle 39 and brain. 40, 41 Alongside analysis of enzymatic fluxes, HP probes can be used to assess perfusion. For this purpose, metabolically inactive probes such as HP 13 C urea can be injected, as demonstrated in tumor imaging by von Morze et al. 42 Further, if copolarized and administered with HP 13 C pyruvate, the combination of HP 13 C pyruvate and HP 13 C urea can provide a simultaneous readout of metabolism and perfusion, as shown by Lau et al. 43 in the rat heart.
Recently, HP 13 C MRS has been demonstrated to be applicable to the detection of neuroinflammation in models of MS 44 and TBI, 45, 46 and more broadly in models of inflammation in the liver 47 and arthritic limb 48 ; all of these studies have taken advantage of the inflammation-related increase in production of HP lactate. In a mouse model of MS, HP [1-13 C] lactate was increased in the corpus callosum, and was associated with a significant increase in activated microglia in that region. This increase was no longer observed in transgenic mice with a deficiency in their ability to activate microglia. 44 HP 13 C MRS has been applied to both a rat 46 and mouse 45 model of TBI. Both studies demonstrated an increase in HP 13 C lactate/pyruvate ratio following injury and, in mice, the depletion of microglia prevented this increase from occurring.
In this study, we hypothesized that HP 13 C MRS could be used to visualize the effect of intracranially administered LPS in the in vivo mouse brain. Given the reports that LPS increases glycolysis in brain microglia and astrocytes, we hypothesized that the induced increase in lactate production could be measured by MRS following administration of HP [1-13 C] pyruvate. We also coadministered HP 13 C urea in order to control for any changes in perfusion that occurred as a result of the injection, and carried out our study at the clinically relevant field strength of 3 T.
Our results showed that, following intracranial injection of LPS in the mouse brain, HP [1-13 C] lactate levels and corresponding HP 13 C lactate/pyruvate ratios were significantly increased at 3 and 7 days post-injection in the ipsilateral (injected) voxel. Moreover, upon normalization to the contralateral side, to the HP 13 C urea, or both, increased HP [1-13 C] lactate levels and increased HP 13 C lactate/pyruvate ratios were systematically observed at the day 7 timepoint in the ipsilateral side of LPS-injected animals. Importantly, the day 7 timepoint corresponded to the maximum levels of Iba1 (resting and activated microglia/macrophages) and glial fibrillary acidic protein GFAP (resting and reactive astrocytes), as detected by immunostaining. Overall, our results show that 13 C MRS of HP [1-13 C] pyruvate and 13 C urea can successfully visualize the effect of LPS on the mouse brain.
| MATERIALS AND METHODS

| Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco.
A total of 28 mice were used in this study. Eleven mice (male C57BL/6 J, aged 10-12 weeks, Jackson Laboratories) underwent the imaging protocol described below prior to surgery (the baseline group). These animals were then injected intracranially with either LPS (n = 6) or saline (n = 5), and the imaging protocol was repeated at 3 and 7 days post-surgery. Separate groups of animals were euthanized at the experimental timepoints (n = 5 baseline, n = 6 at 3 days, n = 6 at 7 days) for histological tissue analysis.
| Intracranial injections
Mice were anesthetized with isoflurane in oxygen (isoflurane: 3% induction, 2% maintenance) and fur was shaved from the tops of their heads.
After placement in a stereotactic frame (Stoelting, IL, USA) and on a heating pad, a small incision was made in the skin to expose the skull. Following orientation using the bregma and lambda to ensure the head was flat, a small hole was made in the skull (1.55 mm to the right and 1 mm to the front of the bregma, to a depth of 2.8 mm), and 5 μl of either saline or 1 mg/ml LPS in saline (0.005 mg; from Escherichia coli O111:B4, Sigma Aldrich) was injected automatically into the striatum using a Hamilton syringe ( Figure 1A ). The syringe was then removed and the wound sutured closed. On removal from the anesthesia, animals were ambulatory after 5-10 minutes.
| MR acquisitions
MR acquisitions were performed on a 3 T horizontal MR system (Bruker Biospec) with a dual-tuned 1 H/ 13 C mouse head volume coil (2 cm diameter, Doty Scientific, SC, USA). Animals were anesthetized with isoflurane (2% in O 2 ) and a 27G tail vein catheter placed before the animal was positioned in a home-built cradle inside the MR system. T 2 -weighted images of the brain were acquired for coregistration of the spectral voxels 
| Histological analysis
Animals were euthanized using an overdose of ketamine/xylazine and then perfused with ice-cold phosphate-buffered saline solution (0.9%), followed by an ice-cold paraformaldehyde (PFA, 4%) solution. The brains were removed and submerged in PFA for 2 hours, before being transferred to a sucrose gradient (5% for 2 hours, 10% for 2 hours, 20% overnight). Brains were then frozen in liquid nitrogen and stored at −80°C.
Cryosections (10 μm) from the imaging voxels were obtained using a microtome (Leica Biosystems, Germany). Immunofluorescence (IF) staining was carried out using the following antibodies: a primary rabbit anti-GFAP (resting and reactive astrocytes, 1:500 dilution, Z0334, Dako), and a primary rabbit anti-Iba1 (resting and activated microglia/macrophages, 1:500 dilution, 019-19741, Wako), both with secondary antibodies goat anti-rabbit fluorescein isothiocyanate (1:500 dilution, 111-096-144, Jackson Immunoresearch Lab), and a primary rat anti-mouse CD68 antibody (activated microglia/macrophages, 1:200 dilution, MCA1957, Biorad) with secondary goat anti-rat Alexa-Fluor 555 (1:200 dilution, A21434, Invitrogen). Slides were counterstained using Hoechst 33342 (H3570, 1:2000 dilution; Invitrogen), then sections were mounted using Prolong Gold Antifade (P36930; Invitrogen).
Immunofluorescence image acquisition was performed using an inverted microscope (Ti, Nikon). The images were recorded with an Andor Zyla 5.5 sCMOS camera at 20x magnification. Quantitative analyses of IF images from the striatum posterior to the injection site within the MRS imaging voxel were performed using NIH ImageJ (v. 2.0.0). Quantification was executed based on coverage and expressed as a percentage of the total area.
| Analysis of hyperpolarized 13 C data
For each animal at each timepoint, HP 13 C 2D CSI data were analyzed using in-house MATLAB code. First, voxel shifts were applied to the raw data to generate data from ipsilateral (injection site) and contralateral voxels (symmetrical from midline, Figure 1A ). Spatial voxel shifting was achieved by applying a linear phase shift to the k-space data prior to Fourier transform. Dynamic spectra over time (shown in grey, Figure 1A ) were summed to generate a summed spectrum (shown in black, Figure 1A ). HP [1-13 C] pyruvate, HP [1-13 C] lactate and HP 13 C urea levels were estimated using a Lorentzian fit. HP 13 C lactate/pyruvate and HP 13 C pyruvate/urea ratios were calculated, and subsequently HP 13 C lactate/(pyruvate/urea) ( Figure S1 ). Heatmaps of individual metabolites' SNR (HP [1-13 C] pyruvate, HP [1-13 C] lactate and HP 13 C urea) were generated at each timepoint using in-house MATLAB code and displayed using SIVIC* ( Figure 2 ). In Figure 3 , all values (individual metabolites and all ratios) have been normalized to data from the contralateral side of the brain to eliminate intra-animal variability.
| Statistical analyses
For all CSI data, a repeated measures one-way analysis of variance (ANOVA) with a Tukey multiple comparisons test was used to establish differences within treatment groups over time, for each side of the brain. Histological data were analyzed using two-way ANOVAs with Tukey multiple comparisons tests to establish significant differences between timepoints and sides of the brain. The graphs show standard deviation, and statistical significance was considered when P ≤ 0.05. Figure S1A ). Figure S1B , HP 13 C lactate/pyruvate ratios were significantly increased in the ipsilateral side of the LPS brains at 3 and 7 days compared with baseline (3 days: 165 ± 28% of baseline, P = 0.046; 7 days: 263 ± 16% of baseline, P = 0.001). This ratio was also significantly increased between 3 and 7 days (Figure S1B; 7 days: 159 ± 27% of 3 day data, P = 0.043). Further, HP 13 C lactate/pyruvate ratios were significantly increased in the contralateral side of the LPS brains at 7 days compared with baseline data ( Figure S1B ; 167 ± 33% of baseline, P = 0.004). In saline-injected animals, no significant changes in HP 13 C lactate/pyruvate ratios were detected in either ipsilateral or contralateral voxels at any timepoints.
| RESULTS
As shown in
No significant changes were observed in HP 13 C pyruvate/urea ratios either in the LPS-or saline-treated animals ( Figure S1B ).
Finally, our results show that the HP 13 C lactate/(pyruvate/urea) ratios were significantly increased at 7 days compared with baseline in the ipsilateral side of the LPS-injected animals ( Figure S1B ; 347 ± 30% of baseline, P = 0.012). No significant changes in this ratio could be observed in either the contralateral side of LPS-injected animals or the ipsilateral and contralateral voxels in the saline-injected animals.
| HP [1-13 C] lactate levels, HP 13 C lactate/pyruvate ratio and HP 13 C lactate/(pyruvate/urea) ratio are increased following LPS injection, upon normalization to contralateral data
Following normalization to contralateral data, our results show that HP [1-13 C] lactate levels were significantly increased in LPS-treated animals at 7 days compared with baseline levels and levels at 3 days (7 days: 164 ± 19% of baseline, P = 0.0007; 136 ± 19% of 3 days, P = 0.018; Figure 3A ).
In the saline-injected group, HP [1-13 C] lactate levels remained unchanged throughout the experimental period. When looking at HP 13 C urea or HP [1-13 C] pyruvate levels, no significant changes in the levels of either metabolite were detected over time in either saline-or LPS-injected groups ( Figure 3A ). Figure 3B , HP 13 C lactate/pyruvate ratios were significantly increased in the LPS brains at 7 days compared with baseline (7 days: 150 ± 28% of baseline, P = 0.0097). In saline-injected animals, no significant changes in HP 13 C lactate/pyruvate ratios were detected at any timepoint. Figure 3B also shows that we observed no significant changes in HP 13 C pyruvate/urea ratios in either LPS-or saline-treated animals.
As shown in
Finally, our results show that the HP 13 C lactate/(pyruvate/urea) ratios were significantly increased at 7 days compared with both baseline and 3 day data (7 days: 169 ± 23% of baseline P = 0.026; 151 ± 23% of 3 day data, P = 0.019; Figure 3B ). No significant changes in this ratio were observed in the saline-injected animals. Figure 4 shows the results for Iba1 (resting and activated microglia/macrophages), CD68 (activated microglia/macrophages) and GFAP (astrogliosis) immunostaining performed in the ipsilateral (I, large square) and the contralateral side (C, small insert) on LPS-injected animals at baseline, 3 and 7 days. All values for immunostaining from saline-injected animals were below 0.16% coverage (data not shown). Figure 4A , Iba1 staining was significantly increased in the ipsilateral side of LPS-treated animals at 7 days compared with baseline and 3 day data, indicating a large number of microglia/macrophages present at that timepoint (7 days: 1096% of baseline, P < 0.0001; 363% of day 3 data, P = 0.0006). At the 7-day timepoint, Iba1 staining was also significantly increased in the ipsilateral side compared with contralateral (835% of contralateral, P = 0.0001). No significant differences between ipsilateral and contralateral sides were observed at baseline or 3 days.
| Iba1, CD68 and GFAP levels are modulated following LPS injection
As shown in
As depicted in Figure 4B , GFAP staining was significantly increased in the ipsilateral side of LPS-treated animals at 7 days compared with ipsilateral baseline and 3 day data (7 days: 48550% of baseline, P < 0.0001; 254% of 3 day data, P = 0.0002). Ipsilateral GFAP staining was also significantly higher at 3 days compared with baseline data (3 days: 19130% of baseline, P = 0.022). Overall, we observed a maximum level of astrogliosis at the day 7 timepoint. When comparing brain sides, our results show that GFAP levels were significantly higher in the ipsilateral voxel than in the contralateral voxel at both 3 and 7 days (3 days ipsilateral: 1733% of contralateral, P < 0.0001; 7 days ipsilateral: 2209% of contralateral, P = 0.0003). Figure 4C shows that CD68 staining was elevated in the ipsilateral side at 3 days postinjection compared with the ipsilateral side at baseline and 7 days, indicating that monocyte activation reached a maximum level at that timepoint (3 day data: 1752% of baseline, P = 0.0008; 557% of day 7 data, P = 0.003). At the 3 day timepoint, CD68 staining was also significantly increased in the ipsilateral side compared with contralateral (2769% of contralateral, P = 0.005). No significant differences between ipsilateral and contralateral sides were observed at baseline or 7 days.
FIGURE 3
All data are shown for baseline (•) and at 3 (◼◻) and 7 days (▲) after surgery, in LPS-and saline-treated groups. Further, all data were normalized to the contralateral side of the brain. A, Data over time for individual metabolites assessed following injection of hyperpolarized [1-13 C] pyruvate. HP [1-13 C] lactate levels were significantly increased in LPS-treated animals at 7 days compared with baseline levels and 3 day data (7 days: 164 ± 19% of baseline, P = 0.0.0007; 136 ± 19% of 3 day data, P = 0.018). B, Ratios for 13 C lactate/ pyruvate, 13 C pyruvate/urea and 13 C lactate normalized to 13 C pyruvate/urea. HP 13 C lactate/pyruvate ratios were significantly increased in the LPS brains at 7 days compared with baseline (150 ± 28% of baseline, P = 0.0097). HP 13 C lactate/(pyruvate/urea) ratios were significantly increased at 7 days compared with both baseline and 3 day data (7 days: 169 ± 23% of baseline, P = 0.026; 151 ± 23% of 3 day data, P = 0.019). *P < 0.05, **P < 0.01, ***P < 0.001
| DISCUSSION
In this study, we demonstrated our ability to image altered brain metabolism following the intracranial injection of LPS. Metabolism was assessed using 13 C MRS following an intravenous injection of HP [1-13 C] pyruvate and HP 13 C urea at the clinicially relevant field strength of 3 T.
Overall, we observed significant changes over time in the detected HP [1-13 C] lactate, HP 13 C lactate/pyruvate and HP 13 C lactate/(pyruvate/ urea) only in the LPS-treated group and not in the saline-injected group. This result is indicative of the fact that the metabolic changes observed at 7 days by HP 13 C MRS were linked to the presence of LPS rather than being a side effect of the surgical procedure.
We did not observe any significant changes in either HP [1-13 C] pyruvate or HP 13 C urea at any timepoint at the group level, which indicates that the in situ delivery of HP substrates is not significantly different between groups. Recent work by Miller et al. has questioned our understanding of the cerebral HP signal, and the authors demonstrated a vast increase in metabolic signal when the blood-brain barrier (BBB) is opened by mannitol, 49 allowing more HP [1-13 C] pyruvate to enter the brain. The literature discussing BBB leakiness as a result of LPS administration is inconclusive, with a review by Varatharaj et al. observing BBB disruption in only 60% of studies considered. 50 Nevertheless, although we have not carried out contrast-enhanced imaging in this study, the fact that we did not observe any significant changes in urea or pyruvate between control and LPS animals suggests that the BBB was not significantly affected by LPS injections. 51 HP [1-13 C] lactate alone was significantly increased at 7 and 3 days compared with baseline in the ipsilateral side of the LPS group. On normalization to HP [1-13 C] pyruvate, which is typically performed to account for variability in pyruvate injection, 31 the change at 7 days was FIGURE 4 Histological analysis of ipsi-and contra-lateral brain slices at each timepoint in the LPS-treated animals. Panels show Iba1, CD68 and GFAP staining examples (contralateral inset), with quantification of percentage coverage. A, Iba1 staining was significantly increased in the ipsilateral side of LPS-treated animals at 7 days compared with baseline and day 3 levels, and at the day 7 timepoint compared with contralateral (7 days: 1096% of baseline, P < 0.0001; 363% of 3 day data, P = 0.0006, 835% of contralateral, P = 0.0001). B, GFAP staining was significantly increased in the ipsilateral side of LPS-treated animals at 7 days compared with ipsilateral baseline and 3 day levels (7 days: 48550% of baseline, P < 0.0001, 254% of 3 day data, P = 0.0002). Ipsilateral GFAP staining was also significantly higher at 3 days compared with baseline data (3 days: 19130% of baseline, P = 0.022). C, CD68 staining was elevated in the ipsilateral side at 3 days post-injection compared with the ipsilateral side at baseline and 7 days (3 day data: 1752% of baseline, P = 0.0008; 557% of 7 days P = 0.003). At 3 days, CD68 was also significantly increased in the ipsilateral side compared with contralateral (2769% of contralateral, P = 0.005). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 exacerbated (P = 0.001 compared with P = 0.036). Not only was ipsilateral HP 13 C lactate/pyruvate significantly increased at 7 and 3 days compared with baseline, but further, at 7 days it was increased compared with 3 days. Upon normalization to HP 13 C urea, the 3-day increase in HP 13 C lactate/pyruvate was no longer significant compared with baseline data. This result may indicate that, although no significant changes were measured when looking at HP 13 C urea or [1-13 C] pyruvate/urea data in group analyses, animal-specific changes in delivery due to experimental technical variabilities (eg, injection rate or percentage polarization of the pyruvate) may have contributed to the increased HP 13 C lactate/pyruvate ratio observed at the day 3 timepoint. However, at the day 7 timepoint, the observed significant increase in HP [1-13 C] lactate production remained following normalization, indicating that the increased HP [1-13 C] pyruvate to HP [1-13 C] lactate conversion was robust enough to be detected by 13 C MRS at 3 T.
HP [1-13 C] pyruvate to HP [1-13 C] lactate conversion was not expected to be altered in the contralateral side of the brain. We observed no significant changes, except for a significantly increased HP 13 C lactate/pyruvate at 7 days compared with baseline. This unforeseen increase may be due to partial volume effects, as the HP 13 C lactate/pyruvate ratio is dramatically increased in the adjacent ipsilateral side at that timepoint (263% increase), or experimental variability between injections. Upon normalization to HP 13 C urea, the HP 13 C lactate/(pyruvate/urea) ratio was no longer different between baseline and 7 days, which demonstrates the value of co-injecting the HP 13 C urea to specifically elucidate metabolic changes, independent of experimental variation in intravenous injections.
To provide an internal normalization, and to account for biological variability between animals, in vivo data were next normalized to the contralateral side of the brain. Once again, significant differences were only observed for HP [1-13 C] lactate, HP 13 C lactate/pyruvate and HP 13 C lactate/(pyruvate/urea) data in the LPS-treated group, but not in saline-injected animals, indicating that the surgical procedure did not affect brain metabolism. Specifically, upon normalization to contralateral data, differences in HP [1-13 C] lactate, HP 13 C lactate/pyruvate and HP 13 C lactate/(pyruvate/urea) between 7-day and baseline data remained highly significant. Differences in HP [1-13 C] lactate and HP 13 C lactate/pyruvate between 3-day and baseline data were no longer observed. For HP [1-13 C] lactate and HP 13 C lactate/(pyruvate/urea) parameters, data were significantly different between 3 and 7 days. Overall, data normalized to contralateral brain strengthen the results from the ipsilateral analyses, confirming that HP [1-13 C] pyruvate to HP [1-13 C] lactate conversion was increased independently of delivery at 7 days compared with baseline.
To confirm the inflammatory response induced by LPS, we carried out histological analysis of animals at each timepoint studied by HP 13 C MRS. Iba1 and GFAP staining confirmed a substantial increase in microglia/macrophages and astrocytes at 7 days following LPS injection, respectively (compared with both 7-day contralateral data and baseline/3-day ipsilateral data). This result was in line with several previous studies 1, 2, 8, 9, 52, 53 ; Go et al. 8 demonstrated a significant increase in microglia at 7 days following an intrahippocampal LPS injection, and Sharma et al. 53 showed a similar increase, this time following an intracerebroventricular injection, and additionally observed an increase in GFAP-positive astrocytes. Future studies could clarify the homogeneity and extent of the LPS response throughout the brain relative to the injection site. However, such experiments are beyond the scope of the current study, which focuses on comparing ipsilateral vs contralateral voxel for validation of the imaging methods.
When considering the histology alongside our in vivo data, our results show that the time of the maximum HP 13 C lactate increase as observed by MRS (7 days) coincided with the time of maximal Iba1 and GFAP staining. An increase in the number or a change in the activation status of these cell types may contribute to the increased HP [1-13 C] pyruvate to [1-13 C] lactate conversion.
Increased numbers of microglia/macrophages and astrocytes in the ipsilateral LPS-injected brain may be responsible for this increased conversion, given the 1096 and 48550% increases in cell types, respectively, compared with baseline values. Resting microglia express the necessary genes for glycolysis 54 ; resting macrophages use both glycolysis and oxidative phosphorylation to produce ATP 55 ; and resting astrocytes have been shown to produce lactate in culture. 56 Therefore, the increase in number alone may be sufficient to be responsible for the increased MRS signal, irrespective of activation status.
Activation of these glial cells may also play a role. CD68, one of the most commonly used markers for microglial activation, showed a significant but small increase in the ipsilateral side of the LPS-treated brain at 3 days compared with baseline and 7 days. Interestingly, this timepoint of maximum activation does not coincide with the timepoint of the maximum HP [1-13 C] lactate signal. However, it is recognized that assessing microglial/macrophage activation is not trivial, and likely necessitates measurement of a wide range of markers; such biological characterization is largely beyond the scope of this study. Investigation of the association between CD68 levels and glycolysis would be required to conclude further on the contribution of CD68-activated microglia to the detected in vivo HP signal. When considering the contribution of astrocytes, maximum astrogliosis was observed at 7 days (the timepoint of maximum HP [1-13 C] lactate). Studies have reported that GFAP levels as measured by IF are linked to reactive astrocytes. [57] [58] [59] It is thus plausible that astrogliosis as observed at 7 days may contribute to the increased HP 13 C pyruvate to 13 C lactate conversion.
Considering activation and cell number, our data suggest that the large increase in the number of both cell types (as assessed by percentage coverage in IF) is likely the driving factor for the increased HP 13 C lactate. However, one cannot distinguish the relative contribution of each cell type to the detected HP [1-13 C] lactate signal. Studies using modulations of microglia or astrocytes levels could help elucidate cell-specific contributions to the HP signal. Guglielmetti et al. 44 showed increased mononuclear phagocytes in the brain alongside increased HP 13 C lactate/pyruvate in a MS model, and in a TBI model 45 demonstrated that increased HP 13 C lactate/pyruvate following injury was no longer observed upon microglial depletion. Similarly, Lewis et al. 60 showed increased lactate production in the heart following a myocardial infarction, which was normalized following monocyte/macrophage depletion. Future bioreactor studies 61 of the individual cell types could also be valuable to decipher the contributions of specific cell types.
Only a few HP studies have been carried out on a preclinical, murine-dedicated 3 T system. 62, 63 This study contributes to the validation of HP acquisitions at this clinically relevant field strength, while taking advantage of the improved gradient strength, leading to higher spatial resolution compared with a clinical 3 T. We opted for a 2D CSI dynamic acquisition instead of a single timepoint to remove potential bias from variability in inter-user injection procedures, which might affect the kinetics of HP [1-13 C] pyruvate and HP [1-13 C] lactate detected by MRS. In future studies, calculations of rates of conversion (k pl ) could be carried out, providing sufficient SNR is achieved, such as in work by Park et al. in the nonhuman primate brain. 64 
| CONCLUSION
We have shown that we can successfully detect increased HP [1-13 C] lactate production in vivo following LPS injection into the mouse brain, coinciding with an increased number of microglia/macrophages and astrocytes as visualized by histology. Many diseases have inflammatory components, and HP 13 C MRS could be a valuable additional tool with which to assess inflammatory status noninvasively and longitudinally.
